Navigation Links
Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia
Date:3/26/2013

ogy. It is being investigated for the treatment of severe hypertriglyceridemia. In preclinical models of severe hypertriglyceridemia, a significant and dose-dependent reduction in plasma triglycerides was observed with CAT-2003, while a simple combination of niacin and omega-3 had only a marginal effect. In preclinical models of dyslipidemia, CAT-2003 dramatically reduced LDL cholesterol.  In combination with a statin, CAT-2003 synergistically lowered LDL cholesterol.  Because CAT-2003 is not activated until it is delivered to the target cell, CAT-2003 is not expected to activate the receptor that causes "niacin flush," a side effect characterized by blushing of the skin and a sensation of warmth resulting from blood vessel dilation; this effect can reduce patient compliance.

About HypertriglyceridemiaSevere hypertriglyceridemia refers to a condition involving levels of triglycerides equal to or above 500 mg/dL. Severe hypertriglyceridemia is associated with markedly increased risk for cardiovascular disease and pancreatitis, and recent studies have demonstrated that elevated triglyceride levels can be regarded as an independent risk factor for cardiovascular events such as myocardial infarction, ischemic heart disease and ischemic stroke.  The prevalence of hypertriglyceridemia is rapidly increasing in the United States and throughout the world.  It is estimated that over four million patients have severe hypertriglyceridemia in the United States. The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol recommends that the first priority for the management of severe hypertriglyceridemia be triglyceride reduction to decrease the risk of pancreatitis. Current treatments include adhering to a low-fat, low-carbohydrate diet, exercise and alcohol abstinence. Medical therapies can include statins to normalize other lipid p
'/>"/>

SOURCE Catabasis Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alliqua Initiates Life-Cycle Management Plan to Expand Wound Care Portfolio for Use in Broader Wound Indications
2. Lithera Initiates Phase 2b Clinical Trial of LIPO-202 Targeting Aesthetic Reduction of Subcutaneous Abdominal Fat
3. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
4. NxStage Initiates 2013 Call to Action Campaign with Launch of Hemodialysis At Home: A Better Way For a Better Life
5. Coyote Pharmaceuticals Initiates GMP Manufacturing Process for CNS-102 Following Successful Pre-IND Meeting
6. Nanomix Initiates Clinical Testing of Point of Care IVD Cardiac Panel
7. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
8. uniQure Initiates Phase I in Acute Intermittent Porphyria
9. Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
10. The Acute Liver Failure Study Group Initiates Phase 2a Study of OCR-002 for Treatment of Acute Liver Failure after Acetaminophen Overdose
11. Isis Pharmaceuticals Initiates Phase 1b/2a Study Of ISIS-SMNRx In Patients With Spinal Muscular Atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 ... signed an exclusive, global license agreement with Plasma ... of its proprietary plasma fractionation process. Concurrently, the ... its intention to strategically refocus and rebrand the ... to pursue a national listing for its common ...
(Date:9/22/2014)... cancer is the second leading cause of cancer death ... early - the problem is that too often it ... Education Council (PCEC), – a national organization committed ... screening –  is sponsoring its 25 th Annual ... Committed to encouraging men to take a ...
(Date:9/22/2014)... -- CytRx Corporation (Nasdaq: CYTR ), a ... announced that study designs and progress from two of ... global Phase 3 clinical trial in relapsed/refractory soft tissue ... in small cell lung cancer, will be presented at ... being held September 26-30, in Madrid, Spain ...
Breaking Medicine Technology:Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 2PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6
(Date:9/22/2014)... Tara Haelle HealthDay ... -- Measuring how quickly a child,s brain processes sounds ... a new study. Observing children,s brainwaves may ... possible, the study authors reported. "The finding that ... associated with autism severity is hugely promising," said senior ...
(Date:9/22/2014)... “The Race is On!” for the 22nd Susan G. ... 2014 as it moves to its new location at Cesar ... fundraising and awareness event for Susan G. Komen® Central and ... the Cure provides supporters of all ages an opportunity to ... in. , “Moving the Race to Cesar Chavez Plaza ...
(Date:9/22/2014)... Mich. Many parents whose kids participate in athletics ... education, but that,s not enough to ensure parents are ... University of Michigan C.S. Mott Children,s Hospital National Poll ... of the 912 parents of middle and high school ... education: , , 23% have read a brochure ...
(Date:9/22/2014)... step for securing critical information systems, such as ... have created a new approach to computer security ... a terminal and automatically logs them out when ... to use their terminal. , Dartmouth,s Trustworthy ... their findings at the IEEE Symposium ...
(Date:9/22/2014)... to laser weapons, the Office of Naval Research (ONR) ... Modern Day Marine exposition that will prepare Marines as ... , ONR program officers will be in Booth No. ... Corps Base Quantico, to discuss how their research contributes ... "fast, austere and lethal." , ONR,s Expeditionary Maneuver Warfare ...
Breaking Medicine News(10 mins):Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 3Health News:Some concussion education more useful than others, parents say 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 3Health News:Modern Day Marine: ONR features technology for marines of the future 2
... causes epileptic seizures, but researchers from Melbournes Howard Florey ... with the help of their newly developed genetically modified ... mutation based mouse model in the world that mimics ... Dr Steven Petrou and his team to understand the ...
... the University of Pennsylvania School of Medicine have found ... the prognosis of patients with head and neck cancers. ... of CANCER. , The belief that a patients psychological ... cancer is one that has been prominent among patients ...
... upbeat, less positive patients , , MONDAY, Oct. 22 (HealthDay ... how long a person with cancer will survive, a ... that among head and neck cancer patients, emotional health ... factor affecting prognosis. , "We anticipated finding that emotional ...
... Sold Exclusively by GE Healthcare Expands Company ... Offerings within Worldwide Hospital Market, ... CSCX ), a global leader in advanced cardiac monitoring,and ... and has begun full shipments of its new "crash ...
... a prescription NSAID (non-steroidal anti- inflammatory drug) treatment that can be applied directly to ... osteoarthritis pain ... in both the knees and the joints ... of the hands * Offers highly effective ...
... and Item finalize settlement agreement with Teva, ... 22 Astellas,Pharma Inc. ("Astellas"; headquarters: Tokyo; ... ("King"; NYSE: KG) and Teva,Pharmaceutical Industries Ltd. ... of Astellas, along with Item Development AB ...
Cached Medicine News:Health News:Childhood epilepsy research offers new hope for seizure control 2Health News:Penn researchers find emotional well-being has no influence on cancer survival 2Health News:Emotional State Doesn't Affect Cancer Survival 2Health News:Emotional State Doesn't Affect Cancer Survival 3Health News:Emotional State Doesn't Affect Cancer Survival 4Health News:Emotional State Doesn't Affect Cancer Survival 5Health News:Cardiac Science Announces Full Shipment of 'Crash Cart' Defibrillator 2Health News:Cardiac Science Announces Full Shipment of 'Crash Cart' Defibrillator 3Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 2Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 3Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 4Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 5Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 6Health News:Adenoscan(R) Patent Lawsuits Settled 2Health News:Adenoscan(R) Patent Lawsuits Settled 3Health News:Adenoscan(R) Patent Lawsuits Settled 4
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTT/1P chairs are recommended for the ... room, static control, health care and ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... ergonomic chairs with concave seats ... support • Select options like ... and glides. • BTT/1P chairs ... environments: industry, education, laboratory, clean ...
Medicine Products: